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Neuroinflammation and Alzheimer´s disease. 
Andrea Varrone1 and Agneta Nordberg2  
Karolinska Institutet, 1Department of Clinical Neuroscience and 2Department of 
Neurobiology, Care Sciences and Society, Stockholm, Sweden 
Abstract 
Neuroinflammatory changes are observed in the brain of patients with Alzheimer´s disease 
(AD). Studies have shown the presence of activated microglia and astrocytes surrounding the 
amyloid plaques, along with the presence of cytokines and other mediators of inflammation. 
The role of inflammation in AD is not yet completely understood. More specifically, some 
inflammatory processes, such as the activation of microglia, may have detrimental or 
beneficial effects on the underlining neuropathology, by promoting inflammation and tissue 
damage or rather phagocytic activity and tissue repair. Imaging of neuroinflammation with 
positron emission tomography (PET) is the only technology that enables the visualization of 
microglia and astrocyte activation in the living human brain. PET studies with first- or second 
generation radioligands binding to the 18-kD translocator protein (TSPO) ([11C]-R-PK11195, 
[11C]DAA1106, [11C]PBR28, [18F]FEMPA) have shown some conflicting results, 
demonstrating on average a ~30% difference in TSPO availability between controls and AD 
patients, with a few studies showing no statistically significant difference between the two 
groups. Similar conflicting evidences have been shown when comparing subjects with mild 
cognitive impairment (MCI) and control subjects. Therefore, whether TSPO is a good marker 
for detecting in vivo microglia activation in AD is still a matter of debate. Imaging of MAO-B 
as a marker for astrocyte activation in AD is a valid alternative to TSPO imaging in the 
context of neuroinflammation. Only limited MAO-B imaging studies with [11C]L-Deprenyl-
D2 are available so far in AD and MCI, showing increased MAO-B binding in MCI patients 
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compared with controls with a degree higher than that observed in AD. There are two unmet 
questions that are still under discussion. The first question is which neuroinflammatory 
process, microglia or astrocyte activation, occurs earlier in the natural course of AD from 
prodromal to dementia stage? Comparative studies using these two markers in MCI and AD 
could be important to clarify which marker could be used for earliest detection of 
neuroinflammatory changes in vivo. The second question is whether imaging of microglia or 
astrocytes per se is a useful marker of neuroinflammation associated with neurodegeneration. 
The development of new radioligands for other targets that are more directly associated with 
the pro- or anti-inflammatory activity of microglia could help understanding the relevance of 
neuroinflammation in the pathological processes leading to neurodegeneration in AD. 
Molecular imaging with PET can be a useful tool to determine the nature and temporal 
evolution of inflammation in early stages of AD in relation to other pathological markers as 
deposition of amyloid plaques and tau as well as clinical presentation of the disease.  
Key Words: TSPO; Alzheimer; microglia; astrocytes 
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Neuroinflammation in Alzheimer´s disease 
The involvement of inflammation in Alzheimer´s disease (AD) is suggested by different 
experimental findings. Epidemiological studies have shown an inverse association between 
the onset of AD and the treatment with anti-inflammatory drugs [1]. The use of anti-
inflammatory drugs might be important in the pre-dementia stage of AD, since clinical trials 
have failed to demonstrate efficacy of anti-inflammatory treatments in patients with mild-to-
moderate dementia [2, 3]. A range of inflammatory processes, such as activated microglia, 
cytokines, activation of complement cascade have been found in the AD brain [4, 5]. The role 
of inflammation in the natural progression of AD is still a matter of debate. Microglia and 
astrocytes are the glial cells involved in the modulation of the inflammatory response and 
repair in the brain [6, 7]. Post-mortem data indicates that microglia and astrocytes are 
associated with amyloid deposition in AD. In post-mortem AD brain tissue, microglia and 
astrocytes are found in the proximity of amyloid plaques [6, 7] (Figure 1) and pre-clinical 
studies in animal models of AD have shown that microglia and astrocytes are recruited around 
the amyloid plaques quite rapidly [8]. Astrocytes are cells that are involved in the reparative 
processes following inflammation and tissue damage. Although it is well acknowledged that 
both microglia and astrocytes are important cells involved in neuroinflammation, their relative 
contribution to the overall neuroinflammatory process is not fully understood. 
Microglia is activated in response to cell damage and might promote a pro-inflammatory 
reaction that contributes to tissue damage and sustained inflammation, or can actively 
promote phagocytosis and tissue repair. A conventional way to indicate these two different 
functions of microglia is the M1/M2 polarization [9]. The M1 phenotype is conventionally 
considered pro-inflammatory, whereas the M2 phenotype is classically seen as anti-
inflammatory. The balance between the two functional types of microglia activation might 
determine the end result of the inflammatory process and neurodegeneration [10]. In the 
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APP/PS1 mouse models of AD, it has been shown that in the hippocampus microglia 
undergoes an age-related phenotypic switch. At 6 months of age, when the A plaque 
pathology develops, the M2 or alternative state with phagocytic capacity is predominant, 
whereas at 18 months of age there is a transition to the classical M1 state, associated with the 
formation of A oligomers and with pyramidal degereneration [11]. The microglia displaying 
M2 phenotype was located mainly around the A plaques and was present also at 18 months, 
at the time of maximal activation of the M1 phenotype [11]. In AD patients it is more difficult 
to examine this transition and studies have found the presence of both activation phenotypes 
of microglia [10]. Therefore, the development of specific radioligands for the two activated 
states of microglia could be helpful to study in vivo the relative contribution and longitudinal 
progression of the M1/M2 phenotypes in relation to AD pathology.    
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PET Imaging of neuroinflammation in AD 
The most established target for noninvasive molecular imaging of neuroinflammation in AD 
is the 18-kD translocator protein (TSPO) [12]. TSPO is expressed on the inner mitochondrial 
membrane of several cells including monocytes, macrophages, microglia and astrocytes [13]. 
The activation of microglia following tissue damage results in an increased density of TSPO 
in the mitochondrial membranes [14]. The increased TSPO expression is not limited to only 
microglia, but also to astrocytes. However, in vitro studies with [3H]-R-PK11195 have shown 
that the binding of this TSPO radioligand in AD brain is more directly associated with 
immunohistochemical markers of microglia rather then astrocytes [15]. Therefore, TSPO 
imaging in AD is classically viewed as a tool to image microglia activation rather than 
astrocyte activation. 
A marker that is more specifically associated with astrocyte activation is the measurement of 
monoamino-oxidase-B (MAO-B) activity. MAO-B in the brain is present in astrocytes and 
serotonin containing neurons [16, 17]. An autoradiographic study using double staining with 
[3H]L-Deprenyl and GFAP-immunohistochemistry showed that the binding of [3H]L-
Deprenyl was in agreement with the GFAP-staining in the white matter of controls and 
patients with amyotrophic lateral sclerosis (ALS) [18]. The selectivity of [3H]L-Deprenyl for 
the binding in reactive astrocytes in ALS patients was confirmed in subsequent studies [19-
21], suggesting that the MAO-B can be a suitable marker for imaging reactive astrocytosis. In 
AD brain, [3H]L-Deprenyl has been shown histochemically to co-localize with GFAP 
immunoreactivity in cell clusters of astrocytes around senile plaques, in amydgala, 
hippocampus and insular cortex [22]. Autoradiographic studies using the tritiated MAO-B 
inhibitors [3H]lazabemide [23], [3H]L-Deprenyl [24] or [11C]L-Deprenyl [25] have also 
shown increase MAO-B binding in the cortex of AD patients and correlation of MAO-B 
signal with GFAP immunoreactivity [23]. Based on these evidences, PET imaging of MAO-B 
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with [11C]L-Deprenyl or the deuterated analog [11C]L-Deprenyl-D2 is considered a marker of 
astrocyte activation in neurodegenerative disorders, including AD. Since L-Deprenyl is a 
suicide inactivator of the MAO-B enzyme [26] and the uptake and distribution of [11C]L-
Deprenyl in the brain has been shown to be influenced by the tracer delivery, particularly in 
regions with high MAO-B content [27], the deuterated analog [11C]L-Deprenyl-D2 has been 
developed [28]. The introduction of deuterium in the molecule decreases the rate of cleavage 
of the carbon-hydrogen bond alpha to the amino group in the propargyl function of L-
deprenyl, thereby decreasing the irreversible trapping of 11C in the brain [28]. The end result 
is that [11C]L-Deprenyl-D2 displays a less irreversible kinetic behavior in the brain and its 
uptake and distribution is more associated to MAO-B activity and less dependent on blood-
flow. For these reasons [11C]L-Deprenyl-D2 is at present the radioligand most widely used to 
image MAO-B activity in the brain with PET. Previous imaging studies with [11C]L-
Deprenyl-D2 have been performed in different neurological disorders such as such as 
epilepsy, Creutzfeldt–Jakob disease and amyotrophic lateral sclerosis (ALS) [29-32]. These 
studies demonstrated increased binding of [11C]L-Deprenyl-D2 in the brain areas involved in 
the pathology of the different disorders, such as the epileptic lobe, the frontal, parietal and 
occipital cortices in Creutzfeldt–Jakob disease, and the white matter and the pons in ALS. 
One aspect to be considered when using [11C]L-Deprenyl-D2 for MAO-B imaging is that 
smokers have reduced brain MAO-B activity as compared with nonsmokers [33] and that 
there is a difference in the arterial input function of [11C]L-Deprenyl-D2 between smokers and 
nonsmokers [34]. These effects of smoking on the delivery and brain uptake of [11C]L-
Deprenyl-D2 may influence the quantification of MAO-B activity in the brain, therefore it is 
recommended to match control and patient groups for smoking or better include only 
nonsmokers in research studies, to avoid possible bias related to the effect of smoking and to 
potential differences in the pharmacokinetic of the radioligand in the body.      
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TSPO imaging in AD 
TSPO has been the target most widely examined in AD and at present there is a plethora and 
redundancy of PET radioligands for that target. From the early development and application 
of [11C]-R-PK11195 [35], a large series of second-generation TSPO radioligands have been 
developed and some of them, such as [11C]DAA1106 [36], [18F]FEDAA1106 [37], 
[11C]PBR28 [38], [18F]FEMPA [39], [18F]DPA-714 [40], and [18F]FEPPA [41], have been 
used to compare TSPO binding in AD vs. control subjects. We focused our review only on 
TSPO imaging in AD and MCI. Previous reviews have discussed the role of imaging of 
neuroinflammation in other forms of dementia, such as Parkinson´s disease dementia, 
frontotemporal dementia and dementia with Lewy bodies [42, 43]. A search of the literature 
using  as  kew  words  “translocator  protein”,  “TSPO”,  “peripheral  benzodiazepine  receptor”,  
“PBR”,  “Alzheimer´s  disease”  and  the  different  radioligands  listed  above  gave  23  results  for  
in vivo clinical studies. In three papers, different quantification approaches for [11C]-R-
PK11195 were presented and although the dataset included also PET data from AD patients 
or MCI subjects, the studies were primarily intended to evaluate the performance of different 
reference tissue models [44-46]. One paper examined the correlation between binding of 
[11C]PBR28 to TSPO in subjects with PARP1 gene variation, but did not provide separate 
data for AD patients and controls [47]. Another paper used data from the ADNI cohort and 
examined the effect of TSPO polymorphism on amyloid load and clinical progression of AD 
but did not included TSPO imaging data in AD patients. The remaining 18 studies were 
designed to specifically compare TSPO binding in AD patients, MCI subjects and elderly 
control subjects and were considered for this review. The summary of the studies conducted 
with [11C](R)-PK11195 and second-generation TSPO radioligands in AD and MCI are 
summarized in Table 1. We have also included one SPECT study using the 123I-labelled 
version of PK11195 [48] and one study with the TSPO radioligand [11C]vinpocetine [49]. 
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Twelve studies have reported different degrees of difference in TSPO binding between AD 
patients and controls [35, 36, 38, 39, 41, 48, 50-52], whereas the remaining six studies have 
not shown any statistically significant difference [37, 40, 49, 53-55]. The brain regions in 
which TSPO binding was found to be significantly higher in AD patients than in controls 
included the prefrontal cortex [36, 38, 41, 48, 50-52, 56], the temporal cortex [35, 36, 38, 39, 
41, 50, 51, 56, 57], the parietal cortex [35, 36, 38, 41, 50, 51, 56, 57], the precuneus [38, 52], 
the anterior cingulate [36, 50-52, 56], the posterior cingulate [35, 38, 39, 50, 52], the occipital 
cortex [38, 41, 50, 56], the amygdala [35, 56], the hippocampus [38, 56], the parahippocampal 
cortex [52, 57], the enthorinal cortex [38, 57], the fusiform gyrus [35], the striatum [35, 36, 
39, 50, 51], and the thalamus [39]. If only the studies showing positive results are considered, 
and excluding one study that used a quantification approach that might have artificially 
produced several-fold differences in BPND between AD patients and control subjects [52], AD 
patients showed higher TSPO binding as compared with control subjects, approximately by 
30% on average. Those studies have used different radioligands and different quantification 
methods and outcome measures, based on the use of a reference time-activity curve or based 
on the measurement of the arterial input function. In four of the studies using second 
generation TSPO radioligands, data were stratified according to the TSPO polymorphism or 
binding status. Interestingly, although the first study conducted with [11C]-R-PK11195 and 
quantification using a supervised cluster analysis has shown very promising results [35], the 
data were replicated only in one subsequent study using the same radioligand [50], whereas 
no statistically significant differences were found in two other [11C]-R-PK11195 studies [54, 
55]. Negative findings have been reported also in two studies using either [18F]FEDAA1106 
[37] or [18F]DPA-714 [40]. The lack of statistically significant differences between AD 
patients and controls can be partly explained with the fact that for both [18F]FEDAA1106 and 
[18F]DPA-714 there was no stratification of the patients by the binding status, likely 
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contributing to the variability of the data and reduced effect size. In the case of the [11C]-R-
PK11195 studies, no obvious reason could explain the lack of statistically significant 
differences between AD patients and controls. One possible explanation could be that the 
measurement of neuroinflammation in vivo using TSPO imaging is not sensitive enough to 
detect differences between patients and controls that can be clearly seen in post-mortem 
studies. Therefore, although [11C]-R-PK11195 is a radioligand with clear limitations for its 
sub-optimal imaging properties, the development of second generation TSPO radioligands has 
not really provided imaging tools that outperform [11C]-R-PK11195.  
In support of the possible explanation that in vivo imaging might not be sensitive enough to 
detect differences between AD patients and controls, two post-mortem studies conducted in 
the late ´80s and early ´90s using [3H]Ro5-4864  (4’-chlorodiazepam) [58] and [3H]PK11195 
[59] did show differences in the binding of the two radioligands between AD patients and 
controls. In the first study using [3H]Ro5-4864 the authors reported a 2-fold higher density of 
peripheral benzodiazepine binding sites in the Broca´s area, postcentral and precentral gyrus 
of AD patients compared with controls. The differences in midtemporal gyrus and frontal pole 
were not statistically significant, although the binding of [3H]Ro5-4864 in AD patients was 
50% to 80% higher than the binding in controls. The second study used Scatchard plots of 
[3H]PK11195 binding in frontal and temporal cortex of controls and AD patients. In frontal 
cortex there was a moderate increase by 40% in Bmax values which showed a trend towards 
statistical significance (p=0.07). On the other hand in temporal cortex, the Bmax values were 
120% higher in AD patients compared with controls. 
These findings were replicated in subsequent post-mortem studies. A 2-fold higher Bmax 
values in hippocampus of AD patients vs. controls was reported using [3H]PK11195 [60]. A 
4-fold higher Bmax values in frontal cortex of AD patients compared with controls were 
found using either [3H]-R-PK11195 or [3H]DAA1106 [15]. Finally, in a recent post-mortem 
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study a 2-fold higher [125I]desfluoro-DAA1106 specific binding was found in the temporal 
and parietal cortex of AD patients as compared with controls [61]. 
There is a major discrepancy between post-mortem and in vivo data concerning TSPO in AD. 
While post-mortem data show 100%-200% higher TSPO binding in AD patients compared 
with controls, the in vivo data show only approximately 30% difference. This discrepancy 
cannot be explained only by the difference in resolution between ARG and PET or by the 
difference in sensitivity between in vitro and in vivo analyses. The discrepancy cannot be 
explained also by the fact that the outcome measure in vitro is Bmax and in vivo is Bmax/KD*fND 
(BPND) or VT (which contains specific and nonspecific binding). In vitro studies have not 
shown differences in KD between AD patients and controls [15, 59] and differences in fND 
should not be expected. One explanation could be that there are other sources of differences 
between in vitro and in vivo conditions. For instance, in hippocampus specimens from AD 
brain it has been shown that 54-kD trimers represent the most abundant form of TSPO [60]. It 
is not known whether the TSPO radioligands bind to TSPO polymers with the same affinity 
as they bind to monomers. If they bind with different affinity to monomers or polymers some 
of the discrepancy might be attributed to the different status of polymerization between in 
vitro and in vivo conditions and between control and AD brains. 
Considering all the possible caveats discussed so far, the main conclusions from the majority 
of the in vivo imaging studies that showed positive results are that only a moderate increase of 
TSPO binding (30%) in AD patients compared with controls can be detected, that a large 
overlap is observed between patients and controls and that when using second generation 
TSPO radioligands it is necessary to stratify for TSPO binding status (Figure 2). If the data of 
the different studies showing positive results are carefully examined, it is clear that beside the 
large overlap, only a fraction of AD patients show TSPO binding levels that are clearly higher 
than controls, see for instance [50] for [11C]-R-PK11195, [36] for [11C]DAA1106, [39] for 
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[18F]FEMPA, [41] for [18F]FEPPA. Therefore, it is possible that not all AD patients have 
increased TSPO expression or microglia activation as measured with TSPO-PET. 
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Methodological aspects of TSPO imaging in AD 
A major aspect that must be considered when reviewing the different studies examining TSPO 
imaging in AD and MCI, is that no consensus has been reached in terms of quantification of 
TSPO binding. Because of the difficulty of measuring adequately the arterial input function of 
[11C]-R-PK11195, the method of choice for the quantification of the binding of [11C]-R-
PK11195 to TSPO has been the supervised cluster analysis [35, 46, 50, 55, 56]. This method 
uses the combination of different kinetic clusters that represent different kinetic behaviors of 
normal GM tissue, pathologic tissue and vascular component. The outcome measure derived 
using this method is the binding potential (BPND). The estimation of BPND is based on the 
assumption that the time-activity curve used as reference tissue is devoid of specific binding. 
This assumption is not true in the case of TSPO, since the density of TSPO is similar to the 
density of other G protein coupled neuroreceptors and cannot be considered negligible [14]. 
In the case of [11C]-R-PK11195 it has been conventionally accepted that the outcome measure 
of choice is BPND, but in reality the outcome measure obtained with [11C]-R-PK11195 is a 
surrogate of BPND, reflecting the ratio between [11C]-R-PK11195  binding  to  “pathological”  
and  “physiological”  tissue.  The acceptance of this violation to the basic assumptions of PET 
quantification has partly been an advantage, since BPND values close to zero can be expected 
in control  subjects, whereas BPND values as low as 0.2-0.5 in AD patients already provide a 
large difference at group level between AD patients and controls [35]. 
The introduction of second generation TSPO radioligands has contributed to examine the 
quantification in more details. Since second generation TSPO radioligands have higher 
affinity for TSPO compared with [11C]-R-PK11195, the level of specific binding associated 
with physiological TSPO expression cannot be neglected and PET quantification must rely on 
accurate measurement of arterial input function and kinetic analysis with compartmental 
modeling. In such case the outcome measure of choice is the total distribution volume, VT. 
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The drawback of VT is not only that arterial cannulation and radiometabolite analysis are 
required, but also that VT contains also a proportion of nondisplaceable binding. In the case of 
[11C]PBR28, for instance, it has been shown that the proportion of nondisplaceable binding is 
approximately 40% of the total binding in all brain regions [62]. Therefore, the use of VT as 
outcome measure for differentiating AD patients from controls might be affected by the 
variability introduced by the measurement of the arterial input function and because of the 
proportion of specific vs total binding that can be different for different radioligands, 
depending on the affinity for TSPO and the amount of nonspecific binding. Two recent 
studies with [18F]FEMPA [39] and [18F]FEPPA [41] have used VT as outcome measures and 
have shown statistically significant higher TSPO binding in AD vs controls when stratifying 
for TSPO binding status. Therefore, VT can be a useful outcome measure provided that 
methodological or biological sources of variability are considered. 
Contrary to the above-mentioned studies, a recent study with [11C]PBR28 has shown that 
using VT as outcome measure does not permit to differentiate statistically AD patients from 
control subjects, whereas using VT normalized by the plasma free fraction of [11C]PBR28, fP, 
permits to detect statistically significantly differences [57]. The use of fP is somewhat 
controversial, because the measurement of fP has itself larger test-retest variability than VT and 
measurements conducted at different centres show indeed different values. In the same study, 
using SUV ratio with the cerebellum as reference region there was a more statistically 
significant difference between AD and controls (higher SUVR values in AD than controls), 
with lower variability of the data. Therefore, using an outcome measure which is less accurate 
than VT but less affected by noise can in principle paradoxically increase the possibility to 
show increased neuroinflammation and TSPO binding in AD. The major question is of course 
if a cerebellum is a suitable reference region in AD. Amyloid plaques can develop in the 
cerebellum, although more likely in the later stages of the disease. In addition, some studies 
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have shown differences in TSPO binding in the cerebellum between AD patients and controls 
[36, 39, 50]. Therefore, the suitability of cerebellum as pseudo-reference region should be 
checked for each TSPO radioligand using full quantification with arterial input function. 
Besides the different quantification methods that might have contributed to the variability of 
the findings reported so far, another aspect to be considered with regards to quantification is 
also the potential interference of radiolabelled metabolites entering the brain. To our 
knowledge, this aspect has not been systematically addressed in the studies reported so far. If 
radiometabolites enter the brain, in theory differences in metabolism between patient groups 
could determine differences in the outcome measures. At least in two studies, the parent 
fraction of [18F]FEDAA1106 [37] and [18F]FEMPA [39] did not differ significantly between 
AD patients and controls, although the findings of the two studies were different (Table 1). If 
this is the case for the other radioligands too, then the differences in metabolism of the TSPO 
tracers should not contribute largely to the differences in the findings observed so far. 
Another methodological aspect that should be considered is related to the analysis of the data. 
For instance, using SPM analysis applied to parametric BPND images clusters of increased 
binding of [11C]-R-PK11195 to TSPO in AD brain have been observed [50, 55], even when 
the ROI-results were negative [55], suggesting perhaps that depending upon the ROI size 
microglia activation might be underestimated using ROI analysis,  because  of  “dilution”  of  the  
increased signal with the normal signal.    
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Neuroinflammation in prodromal AD 
Neuroinflammation is a condition that is clearly related to amyloid deposition in the brain and 
that most likely follow a certain time course in parallel with amyloid deposition. To our 
knowledge there are no longitudinal studies examining the changes of TSPO binding over 
time. However, cross sectional studies have examined subjects with mild cognitive 
impairment (MCI), a condition representing a prodromal stage of AD. These studies have 
used [11C]-R-PK11195 and second generation TSPO radioligands and have reported either no 
statistically significant differences between MCI subjects and controls or AD patients [38, 54, 
55] or a mild-to-moderate increase of TSPO binding between 17% and 41% in MCI subjects 
compared with either AD patients or controls [51, 63] [56]. The regions in which TSPO 
binding was significantly higher in MCI subjects than in controls included the prefrontal 
cortex [51, 56, 63], the temporal cortex [51, 56], the parietal cortex [51, 56], the anterior 
cingulate [51, 56], the posterior cingulate [56], the amygdala [56], the hippocampus [56], and 
the striatum [51].  The amyloid load does not seem to always correlate with the level of TSPO 
binding in AD [50, 63] and the differences in TSPO binding between MCI and controls or 
between MCI and AD do not seem to be largely influenced by the presence of absence of 
amyloid in the brain [38, 54, 63]. 
Some studies have though shown significant correlation between amyloid load and TSPO 
binding in the posterior cingulate cortex [52] or in several brain regions typically involved in 
AD pathology such as frontal cortex, temporo-parietal cortex, cingulated cortex and 
parahippocampal gyrus [56]. This last study used an advanced method of voxel-based analysis 
based on the correlation of binding potential between voxels of [11C]PIB and [11C]PK11195 
parametric images. In the same study a correlation between amyloid load and TSPO binding 
was also found in MCI subjects in similar brain regions as in AD patients [56]. 
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At present, it is difficult to conclude whether neuroinflammation can be detected in vivo with 
PET already at early or prodromal stages of AD and whether the presence of 
neuroinflammation can be a finding predictive of longitudinal progression of the disease or of 
clinical deterioration in MCI subjects. The only study that attempted to examine the 
relationship between TSPO binding and conversion to dementia reported that MCI subjects 
with binding potential values of [11C]DAA1106 higher than the control mean +0.5 standard 
deviation developed dementia within 5 years [51]. Further studies are needed to confirm these 
findings and to establish whether the presence of neuroinflammation can be predictive of 
conversion to dementia. 
Imaging of neuroinflammation can be extremely valuable as imaging marker to assess direct 
or indirect anti-inflammatory effects of new drugs with potential disease modifying 
properties. Therefore, imaging neuroinflammation with PET in MCI or AD can be a valuable 
tool for proof-of-mechanism studies and clinical trials with anti-inflammatory drugs. 
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Neuroinflammation and cognitive function 
It is acknowledged that in AD there is no straightforward correlation between amyloid load 
and cognitive function and that most likely tau pathology is more correlated with cognitive 
impairment. The relationship between neuroinflammation, measured with TSPO imaging, and 
cognitive function has been investigated in several studies. Studies with [11C]-R-PK11195 
[50], [11C]PBR28 [38] and [18F]FEPPA have reported a statistically significant negative 
correlation between MMSE or neuropsychological tests of memory function and TSPO 
binding in brain regions typically involved in AD, such as posterior cingulate, frontal, 
temporal and parietal cortex. Other studies did not report any statistically significant 
correlation between measures of cognitive function and TSPO binding examined with [11C]-
R-PK11195 or [11C]DAA1106 [51, 52, 55]. One study has reported statistically significant 
negative correlation between [11C]-R-PK11195 binding and MMSE in amyloid-negative but 
not amyloid-positive AD patients [63]. Despite some controversies in the results obtained by 
different groups, the overall findings suggest some link between neuroinflammation and 
cognitive impairment in AD.             
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Microglia or astrocytes? 
As discussed previously, TSPO is conventionally seen as a marker of activated microglia, 
although the protein is expressed also in astrocytes, whereas MAO-B is considered a marker 
of activated astrocytes. At present, the only well-established radioligand available for imaging 
MAO-B activity in humans with PET is [11C]L-Deprenyl-D2. Contrary to the literature on 
TSPO, there are only a few studies conducted in AD patients and MCI subjects using [11C]L-
Deprenyl-D2. These studies show an increase of cortical and hippocampal binding of [11C]L-
Deprenyl [25] or [3H]L-Deprenyl [64] in vitro in post-mortem AD brain tissue. The [3H]L-
Deprenyl binding showed a distinct different pattern from the [3H]Pittsburgh compound B 
(PIB) binding fibrillar amyloid plaques. Quantitative autoradiography demonstrated a clear 
laminar pattern of [3H]L-Deprenyl binding in the frontal cortex whereas high [3H]PIB binding 
was observed in all layers [64]. The first in vivo study conducted in an AD population 
examined the inhibition of MAO-B activity measured with [11C]L-Deprenyl-D2 using a 
selective MAO-B inhibitor [65]. A subsequent study with [11C]L-Deprenyl-D2 has shown 
high binding in AD patients [66], while interestingly enough in one study PIB positive MCI 
subjects showed higher binding of [11C]L-Deprenyl-D2 in brain as compared with both AD 
patients (Figure 3) and healthy controls [67]. In addition, in PIB positive MCI subjects, the 
binding of [11C]L-Deprenyl-D2 in the para-hippocampus has been shown to be inversely 
related to the grey matter density in the same region [68], suggesting a link between astrocyte 
activation and neurodegeneration in prodromal AD. High [11C]L-Deprenyl-D2 binding has 
been shown also in pre-symptomatic subjects with familiar AD [69] and in transgenic mice 
carrying the APPswe mutation, in which increased MAO-B activity measured with [11C]L-
Deprenyl-D2 microPET was present already at 6 months, whereas amyloid deposition 
measured with [11C]AZD2184 was significantly increased only at 18-24 months [70]. These 
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studies in prodromal AD and in animal models of AD suggest that astrocyte activation is an 
early pathological finding in AD. 
PET imaging of TSPO and MAO-B have been combined with amyloid imaging to examine 
the relationship between amyloid deposition and neuroinflammation. Although amyloid 
deposition and activated microglia or astrocytes are present in similar brain regions, 
suggesting the co-localization of both phenomena, the amyloid load does not necessarily 
correlate with TSPO binding or MAO-B activity in the brain. The relationship between 
amyloid deposition and neuroinflammation is not completely straightforward but 
accumulating data suggest that the two processes are linked to each other, which is also 
indicated by the high presence of astrocytes found close to the amyloid plaque formations [6].  
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Conclusions 
Several evidences from pathological as well as in vivo PET studies in human subjects indicate 
the involvement of microglia and astrocytes in neuroinflammatory processes associated with 
AD. Despite many contributions to the field of molecular imaging of neuroinflammation, 
some important questions remain to be address, to better understand the relative contribution 
of microglia and astrocytes in AD pathology. How much of the TSPO binding in vivo is 
associated to microglia or astrocytes? Is the type of microglia that expresses TSPO mainly 
pro-inflammatory or anti-inflammatory? The first question could benefit of combined PET 
studies in prodromal and clinical AD stages with TSPO and MAO-B radioligands, to 
understand which process, microglia or astrocyte activation, occurs first in relation to amyloid 
deposition. The second question could benefit of the development of specific radioligands 
targeting M1 or M2 types of microglia. Radioligand development in the area of 
neuroinflammation beyond TSPO is very important to try to understand better the process of 
neuroinflammation in neurodegenerative disorders. After many years of work in trying to find 
the most suitable TSPO PET radioligand, the major challenge for the coming years will be to 
develop radioligands for novel and more specific targets of neuroinflammation to be used as 
early diagnostic markers as well as evaluation of new drug targets for treatment of AD and 
related dementia disorders.
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Figure Legend 
Figure 1. Amyloid plaques and astrocyte and microglia distribution in the frontal cortex of 
Alzheimer brain. Sections from the frontal cortex Alzheimer brain were double stained with 
amyloid antibody 4G8 (Aß17-24), 6E10 (Aß1-17) in combination with anti-GFAP 
(astrocytes) and Iba1 (microglia) antibodies. 40 times magnification. Photo courtesy of Dr 
Larysa Voytenko, Karolinska Institutet. 
Figure 2. Transaxial images of [18F]FEMPA obtained in high affinity binding subjects, 
showing higher binding of the radioligand in the brain of AD patients compared with control 
subjects. The unit of radioactivity was expressed as standardized uptake value (SUV). The 
PET images were obtained by averaging the frames between 60 and 90 minutes. Image 
courtesy of Andrea Varrone, Karolinska Institutet, Juha Rinne, Turku PET Centre, Ana 
Catafau, Piramal Imaging. 
Figure 3. High astrogliosis in the brain of patient with cognitive impairment associated with 
high  β-amyloid load (PIB+)  indicative of prodromal AD (left panel) in comparison with 
clinically  demented  patient  with  Alzheimer’s  disease  (AD;;  right  panel).  Representative  
parametric images of [11C]-L-deprenyl-D2 binding (that reports monoamine-oxidase activity 
in astrocytes) were obtained by position emission tomography. The positron emission 
tomography scans show sagittal sections of the brain at the level of basal ganglia. Color scale: 
red = very high, yellow = moderate high, green = high, blue = low [11C]-L-deprenyl-D2 
binding. Image courtesy of Agneta Nordberg, Karolinska Institutet. 
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Table 1. Summary of in vivo TSPO imaging studies in Alzheimer´s disease and MCI. 
Author  Patients  Radioligand  PIB  PVEc  Outcome measure – 
method  
Increase of TSPO 
binding (%) vs. 
controls 
Groom, 1995 8 AD [11C]PK11195a No No Region-to-cerebellum 
ratio 
n.s.  
Cagnin, 2001 8 AD, 1MCI [11C]-R-PK11195 No No BPND – supervised 
cluster analysis 
35-188% 
Versijpt, 2003 10 AD [123I]PK11195 No No Region-to-cerebellum 
ratio 
32% 
Edison, 2008  13 AD  [11C]-R-PK11195  Yes  No  BPND – supervised 
cluster analysis  
23%  
Yasuno, 2008  10 AD  [11C]DAA1106  No  No  BPND (k3/k4) – 2TCM  17%  
Wiley, 2009  6 AD, 6 MCI  [11C]-R-PK11195  Yes  Yes  BPND – supervised 
cluster analysis 
(cerebellum)  
n.s.  
Okello, 2009  22 AD, 14 MCI  [11C]-R-PK11195  Yes  No  BPND – supervised 
cluster analysis  
9-23% AD, 
17-25% MCI  
Gulyás, 2011 6 AD [11C]vinpocetine No No SUV, SUVR and BPND 
(cerebellum) 
n.s. 
Yokokura, 2011b 11 AD [11C]-R-PK11195  Yes No BPND – SRTM with 
normal brain TAC as 
reference  
118-1100% 
Table 1
Yasuno, 2012  10 AD, 7 MCI  [11C]DAA1106  No  No  BPND (k3/k4) – 2TCM  18% AD, 26% MCI  
Schuitemaker, 2013  20 AD, 13 MCI  [11C]-R-PK11195  No  Yes  BPND – supervised 
cluster analysis  
n.s.  
Varrone, 2013  9 AD  [18F]FEDAA1106  No  No  VT - Logan GA  n.s.  
Kreisl, 2013c  19 AD, 10 MCI  [11C]PBR28  Yes  Yes  VT / fP – 2TCM  38% AD  
Varrone, 2015c  10 AD  [18F]FEMPA  No  No  VT - Logan GA  19.5% (HABs)  
Golla, 2015 10 AD [18F]DPA-714 No No VT – 2TCM n.s. 
Lyoo, 2015c 25 ADc, 11 MCIc [11C]PBR28  Yes No VT – 2TCM 
VT / fP – 2TCM 
DVR (cerebellum) 
SUVR (cerebellum) 
n.s.(VT) 
22-25% AD (VT / fP) 
8-14% (DVR) 
6-10% (SUVR) 
Suridjan, 2015c 21 AD [18F]FEPPA No Yes VT – 2TCM 44-56% 
Fan, 2015 10 AD, 10 MCI, 
11 PDD 
[11C]-R-PK11195  Yes No BPND – supervised 
cluster analysis 
40.5% AD, 41% MCI 
 
aIn this study it is not specified if the racemic mixture of PK11195 or the R enantiomer was used. 
 bThis study used the average time-activity curve (TAC) from the control subjects as indirect input function for the estimation of BPND in both the 
AD and control groups. This approach might have produced values of BPND close to 0 in the control group, thereby leading to BPND in the AD 
group that was several-fold higher than the controls.  
bThese studies used stratification or adjustment for TSPO binding status. 
cSome of these patients were already included in a previous study from the same group (Kreisl, 2013). 
PVEc=partial volume effect correction. 
PDD=Parkinson´s disease dementia. 
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binding is high, a reference tissue approach should still be able to measure specific binding 
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